FULCRUM THERAPEUTICS

Fulcrum Therapeutics Reports Recent Business Highlights and First Quarter 2022 Financial Results

09 5 2022 07:00:02 提供 Nasdaq GlobeNewswire

Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 5 2022 08:00:00 提供 Nasdaq GlobeNewswire

Fulcrum Therapeutics to Participate at the Upcoming BofA Securities 2022 Healthcare Conference

05 5 2022 08:00:01 提供 Nasdaq GlobeNewswire

Fulcrum Therapeutics to Host First Quarter 2022 Financial Results Conference Call and Webcast on Monday, May 9, 2022 at 8:00 a.m. ET

02 5 2022 08:00:02 提供 Nasdaq GlobeNewswire

Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

08 4 2022 08:00:00 提供 Nasdaq GlobeNewswire

Fulcrum Therapeutics® Announces Multiple Presentations on FSHD at the American Academy of Neurology’s Annual Meeting

01 4 2022 08:30:00 提供 Nasdaq GlobeNewswire

Fulcrum Therapeutics® to Host Virtual Key Opinion Leader Webcast Featuring Losmapimod for Facioscapulohumeral Muscular Dystrophy (FSHD)

17 3 2022 08:00:02 提供 Nasdaq GlobeNewswire

Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

11 3 2022 08:00:00 提供 Nasdaq GlobeNewswire

Fulcrum Therapeutics® Reports Recent Business Highlights and Fourth Quarter and Full Year 2021 Financial Results

03 3 2022 07:01:00 提供 Nasdaq GlobeNewswire

Fulcrum Therapeutics® Announces REACH, a Phase 3 Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)

03 3 2022 07:00:01 提供 Nasdaq GlobeNewswire

Fulcrum Therapeutics® to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call and Webcast on Thursday, March 3, 2022 at 8:00 a.m. ET

24 2 2022 08:00:02 提供 Nasdaq GlobeNewswire

Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

11 2 2022 08:00:00 提供 Nasdaq GlobeNewswire

Fulcrum Therapeutics® to Participate in 11th Annual SVB Leerink Global Healthcare Conference

10 2 2022 08:00:01 提供 Nasdaq GlobeNewswire

Fulcrum Therapeutics® Announces Upcoming Milestones to Support Its Mission of Treating the Root Cause of Rare Genetic Diseases

10 1 2022 07:00:03 提供 Nasdaq GlobeNewswire

Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

07 1 2022 08:00:00 提供 Nasdaq GlobeNewswire

Fulcrum Therapeutics® to Present at the 40th Annual J.P. Morgan Healthcare Conference

06 1 2022 08:00:01 提供 Nasdaq GlobeNewswire

Fulcrum Therapeutics® Appoints Esther Rajavelu as Chief Financial Officer

04 1 2022 08:00:02 提供 Nasdaq GlobeNewswire

Fulcrum Therapeutics® Announces Additional HBG mRNA Induction from Higher Dose Cohorts in Phase 1 Healthy Adult Volunteer Trial of FTX-6058 for Sickle Cell Disease and New Preclinical Mechanism Data

06 12 2021 07:00:01 提供 Nasdaq GlobeNewswire

Fulcrum Therapeutics® Appoints Sonja L. Banks to its Board of Directors

17 11 2021 08:00:01 提供 Nasdaq GlobeNewswire

Fulcrum Therapeutics® Reports Recent Business Highlights and Third Quarter 2021 Financial Results

04 11 2021 07:00:02 提供 Nasdaq GlobeNewswire